Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Relapsing Multiple Scelrosis
Interventions: Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 59
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: George Washington University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hyperactive Delirium, Mixed Delirium
Interventions: Valproic Acid, Placebo, Haloperidol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pain Associated With Fibromyalgia
Interventions: DS-5565, Pregabalin, Placebo tablet, Placebo capsule; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 92
States / cities: Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 89 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions: Vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Norovirus
Interventions: CDI-988, Placebo, Snow Mountain Virus; Drug · Other
Lead sponsor: Cocrystal Pharma, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Partial Seizures, Epilepsies, Partial
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 26
States / cities: Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Lung Cancer
Interventions: Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 21
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 56
States / cities: Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more

Conditions: Obesity, Overweight
Interventions: Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide), Placebo II (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 50
States / cities: Buena Park, California • Concord, California • Fresno, California + 42 more

Conditions: Healthy
Interventions: Beetroot Juice, Placebo Control; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Dallas, Texas • Waco, Texas

Conditions: Chronic Lymphocytic Leukemia
Interventions: Idelalisib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Fullerton, California • La Jolla, California • Santa Maria, California + 20 more

Conditions: Functional Constipation in Children Ages 6-17 Years
Interventions: Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 60
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more

Conditions: Ebola
Interventions: Ad26.ZEBOV, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 974 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more

Conditions: Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: MK-5720, Placebo to MK-5720, MK-8189, Placebo to MK-8189; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more

Conditions: Obesity, Obese
Interventions: HM17321, Placebo of HM17321; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Temanogrel, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Pneumococcal Infections
Interventions: V114, QIV, Matching Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more

Conditions: Healthy
Interventions: AZD9742, Placebo to match AZD9742; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Multiple Myeloma
Interventions: Siltuximab, Bortezomib, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 11
States / cities: Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: Alport Syndrome
Interventions: lademirsen (SAR339375), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 150
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more

Search by objective public record fields.

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

Treatment of Pain Associated With Fibromyalgia

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Once-A-Day Pregabalin For Partial Seizures

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Beetroot Juice for Boosting Immunity During a Time of Stress.

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH